Compare Edwards Lifesciences Corporation Common Stock (EW) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Global X Uranium ETF — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B), while Global X Uranium ETF trades at $38.96 (market cap $5.81B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 8.5× Global X Uranium ETF's market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| EW | URA | |
|---|---|---|
Market Cap | $49.44B | $5.81B |
Volume | 3,508,027 | 4,014,301 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $95.18 | $61.81 |
52-Week Low | $72.65 | $37.52 |
Enterprise Value | $45.90B | — |
Typical Hold Time | — | 62 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
URA (Global X Uranium ETF) is trading at $39.93, down 4.47% over the past 24 hours amid bearish technical signals. The ETF faces selling pressure with 16 technical indicators signaling sell versus only 1 buy signal. Recent news highlights nuclear energy's growth potential driven by AI power demand and government support, but uranium ETFs have experienced significant volatility with a 30% correction in August 2026 despite positive sector fundamentals.
The long-term outlook remains positive given nuclear energy's role in meeting AI and electrification demands, with the U.S. targeting 300GW of new nuclear capacity by 2050. Key risks include commodity price volatility and single-stock concentration, while opportunities exist through diversified exposure to the nuclear supply chain. Current technical weakness suggests potential for further consolidation before resuming upward trend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
